
Cassava Sciences Investor Relations Material
Latest events

Status Update
Cassava Sciences

Q1 2025
8 May, 2025

Q4 2024
3 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cassava Sciences Inc
Access all reports
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, with a primary focus on Alzheimer’s disease. The company’s leading drug candidate, simufilam, is an oral small molecule in 3 clinical trials aimed at treating Alzheimer’s by targeting an altered form of a brain protein known as filamin A. Cassava Sciences is also developing SavaDx, an investigational diagnostic tool designed to detect Alzheimer's disease through a blood test. The company is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
)
Ron Vachris: From Forklift Driver to CEO at Costco
Ron Vachris took over as Costco CEO in 2024, following a 40-year journey from warehouse floors to the top of one of retail's most admired companies.
18 Jun 2025
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
Ticker symbol
SAVA
Country
🇺🇸 United States